Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2025 08:30 ET | Source: Vivos Inc.

Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization

Kennewick, WA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc filed a provisional patent No.: 63/873,014 - STERILE THERMOGELS Vivos Inc. is pleased to announce the successful...
August 14, 2025 08:30 ET | Source: Vivos Inc.

Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA

Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined approval of the Radiogel® IDE submission. We are now focused on...
February 04, 2025 08:00 ET | Source: Vivos Inc.

Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans

Richland, WA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to report that the first five patients demonstrated the safety of RadioGel Precision Radionuclide TherapyTM by...
January 11, 2023 09:30 ET | Source: Vivos Inc.

Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy

Richland WA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision...
January 03, 2023 09:30 ET | Source: Vivos Inc.

Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment

Richland WA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a provisional patent application on the system equipment to support precision...
May 12, 2022 09:30 ET | Source: Vivos Inc.

Vivos Inc. Provides Intellectual Property Protection Update

Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts. Our patent team filed...
January 24, 2022 09:30 ET | Source: Vivos Inc.

Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives

Richland WA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2022, we wanted to...
June 24, 2021 09:30 ET | Source: Vivos Inc.

Vivos Inc Initiates Isopet® Therapy in Horses

Richland WA, June 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc announced that it has completed the first IsoPet® therapy on an equoid tumor. It was administered at the University...
December 07, 2020 09:30 ET | Source: Vivos Inc.

Vivos Inc to Present at The 13th Annual LD Micro Main Event Conference December 15, 2020 11:00 AM Eastern Standard Time

Richland WA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL``), Vivos Inc (RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of...
September 03, 2020 09:30 ET | Source: Vivos Inc.

Vivos Inc Initiates IsoPet Therapy of Horses – Addressing Unmet Need for the Treatment of Equine Tumors

Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet® into the equine market by making IsoPet® available to...